Floatz logo

cd19cat-41bbz car t-cells

Hematopoietic/Lymphoid Cancer

Xuzhou Medical UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Hematopoietic/Lymphoid Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
Zofran
Yale University
Phase 3BB
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
Granisetron
Alliance for Clinical Trials in Oncology
Phase 3BB
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 26 →

Same molecule, other indications

cd19cat-41bbz car t-cells is also rated in:

acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →